EA9161 A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)

January 19, 2021
https://www.clinicaltrials.gov/ct2/show/NCT03701282
Cancer - Leukemia
Principal Investigator: Ding Wang, MD
cancer, blood cancer, leukemia, lymphocytic leukemia
Accepting Participants